Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Asset disposition
Inv. presentation
Quarterly results
CC transcript
Credit agrmnt [a]
Acq. announced
Appointed director
|
|
IMPAX LABORATORIES INC (IPXL)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 12/19/2017 |
8-K/A
| Material Impairments |
| 10/19/2016 |
8-K/A
| Financial Statements and Exhibits|
Docs:
|
"Consent of PricewaterhouseCoopers LLP related to the special purpose combined financial statements of Certain Pharmaceutical Products of Teva Pharmaceutical Industries Limited",
"Consent of PricewaterhouseCoopers LLP related to the special purpose combined financial statements of Certain Pharmaceutical Products of Allergan plc",
"Audited special purpose combined financial statements of Certain Pharmaceutical Products of Teva Pharmaceuticals Industries Limited, comprised of the special purpose combined statements of assets acquired as of December 31, 2015 and December 31, 2014 and the related special purpose combined statements of revenue and direct expenses for each of the three years in the period ended December 31, 2015, and the related notes, for the Acquired Product Lines",
"Audited special purpose combined financial statements of Certain Pharmaceutical Products of Allergan plc, comprised of the special purpose combined statements of assets acquired as of December 31, 2015 and December 31, 2014 and the related special purpose combined statements of revenue and direct expenses for each of the three years in the period ended December 31, 2015, and the related notes, for the Acquired Product Lines",
"Unaudited special purpose combined interim financial statements of Certain Pharmaceutical Products of Teva Pharmaceuticals Industries Limited, comprised of the special purpose combined statements of assets acquired as of June 30, 2016 and the related special purpose combined statements of revenues and direct expenses for the six month periods ended June 30, 2016 and June 30, 2015, and the related notes, for the Acquired Product Lines",
"Unaudited special purpose combined interim financial statements of Certain Pharmaceutical Products of Allergan plc, comprised of the special purpose combined statements of assets acquired as of June 30, 2016 and the related special purpose combined statements of revenues and direct expenses for the six month periods ended June 30, 2016 and June 30, 2015, and the related notes, for the Acquired Product Lines",
"Unaudited pro forma combined balance sheet as of June 30, 2016 and statements of operations for the year ended December 31, 2015 and the six months ended June 30, 2016, and the related notes, of Impax Laboratories, Inc" |
|
| 05/22/2015 |
8-K/A
| Submission of Matters to a Vote of Security Holders |
| 05/15/2015 |
8-K/A
| Financial Statements and Exhibits |
| 04/02/2012 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 03/02/2011 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 05/28/2010 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 12/08/2005 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 09/28/2005 |
8-K/A
| Form 8-K/A - Current report [Amend] |
| 06/28/2005 |
8-K/A
| Form 8-K/A - Current report [Amend] |
|
|